A review of pomegranate in prostate cancer.
A review of pomegranate in prostate cancer.
复制标题
DOI：
10.1038/pcan.2017.19
复制
发表时间：
2017-09
影响因子：
4.8
通讯作者：
Carducci MA
中科院分区：
文献类型：
--
作者：
Paller CJ;Pantuck A;Carducci MA
临床前研究表明，石榴汁及其成分抑制前列腺癌，导致了多项临床试验，以确定石榴产品是否可以减缓前列腺癌的生长。这篇综述总结了临床前的数据并讨论了临床试验的结果。试验对象为积极监测的患者、新辅助治疗患者、前列腺癌局部治疗后生化复发(BCR)患者以及转移性去势抵抗前列腺癌(MCRPC)患者。在BCR患者群体中，石榴汁和提取物的早期II期试验显示PSA倍增时间(PSADT)显著延长，并证实了石榴产品的安全性。虽然一项安慰剂对照的III期试验确定石榴提取物没有显著延长BCR患者的PSADT，但对携带锰超氧化物歧化酶(MnSOD)AA基因的患者进行的预先计划的亚组分析显示，石榴提取物手臂的PSADT延长幅度更大。在新辅助剂人群中，一项大型试验显示，与安慰剂组相比，石榴组患者的尿磷脂A显著增加，而前列腺癌组织中氧化的标志物8-OHdG没有显著下降。此外，一项富含多酚的多组分食品补充片的随机临床试验，包括31.25%的石榴提取物，发现在积极监测和经历生化复发的男性中，食品补充剂组与安慰剂相比，PSA的增加显著放缓。在一项大型安慰剂对照试验中，石榴汁和提取物是安全的，但并未显著改善BCR患者的预后。然而，一部分携带MnSODAA基因的bcr患者似乎对石榴治疗的抗氧化作用有积极的反应。在新佐剂患者和mCRPC患者中100%石榴制品的II期试验均为阴性。在积极监测和BCR患者的II期研究中，一种多组分食品补充剂显示了良好的结果。
Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC). In the BCR patient population, early phase II trials of both pomegranate juice and extract showed significant lengthening of PSA doubling time (PSADT), and confirmed the safety of pomegranate products. While a placebo-controlled phase III trial determined that pomegranate extract did not significantly prolong PSADT in BCR patients, a preplanned subset analysis of patients with the manganese superoxide dismutase (MnSOD) AA genotype showed greater PSADT lengthening on the pomegranate extract arm. In the neoadjuvant population, a large trial demonstrated a significant increase in urolithin A and a non-significant reduction in 8-OHdG, a marker of oxidation in prostate cancer tissue, on the pomegranate arm vs. the placebo arm. In addition, a randomized clinical trial of a polyphenol-rich multi-component food supplement tablet, including 31.25% pomegranate extract, found significant slowing of PSA increase in the food supplement arm vs. placebo in men on active surveillance and those experiencing biochemical recurrence. Pomegranate juice and extract are safe but did not significantly improve outcomes in BCR patients in a large placebo controlled trial. However a subset of BCR patients with the MnSOD AA genotype appear to respond positively to the antioxidant effects of pomegranate treatment. Phase II trials of 100% pomegranate products in neoadjuvant patients and patients with mCRPC were negative. A multi-component food supplement showed promising results in a phase II study in active surveillance and BCR patients.
登录
查看更多内容
影响因子：
3.7
作者：
Iguchi T;Wang CY;Delongchamps NB;Kato M;Tamada S;Yamasaki T;de la Roza G;Nakatani T;Haas GP
通讯作者：
Haas GP
影响因子：
--
作者：
Patterson, RE;Neuhouser, ML;Bowen, DJ
通讯作者：
Bowen, DJ
影响因子：
4.8
作者：
Pantuck, A. J.;Pettaway, C. A.;Heber, D.
通讯作者：
Heber, D.
影响因子：
3.8
作者：
Kim, ND;Mehta, R;Lansky, E
通讯作者：
Lansky, E
DOI：
10.1073/pnas.171326098
发表时间：
2001-08-28
影响因子：
11.1
作者：
Gupta, S;Hastak, K;Mukhtar, H
通讯作者：
Mukhtar, H